HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

57.000

+1.2502.24%

Volume:1.73M

Turnover:99.35M

Market Cap:11.34B

PE:-40.20

High:59.150

Open:57.050

Low:55.400

Close:55.750

52wk High:97.500

52wk Low:44.720

Shares:199.00M

HK Float Shares:198.00M

Volume Ratio:0.76

T/O Rate:0.87%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-1.418

ROE:-51.55%

ROA:-12.87%

PB:10.40

PE(LYR):-40.20

PS:45.39

Loading ...

Overview Company News Filings

Nanjing Leads Biolabs Says Phase II Opamtistomig Trial in First-Line Liver Cancer Enters Expansion Phase

Leads Biolabs: Phase II Opamtistomig Trial for First-Line Liver Cancer Enters Expansion Stage

Bulletin Express

LEADS BIOLABS-B Advances Phase II Study of Vilitis™ in Hepatocellular Carcinoma to Expansion Stage

Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of Lbl‑051 for Refractory Autoimmune Diseases

THOMSON REUTERS

Leads Biolabs’ partner Oblenio opens Phase Ia trial for trispecific T-cell engager LBL-051; company clarifies connected share-award transaction

Bulletin Express

Nanjing Leads Biolabs Clarifies Award Grant to Executive Director is Exempt Connected Transaction Under HK Rules

Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Ind Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise

THOMSON REUTERS

LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment

LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total

Nanjing Leads Biolabs Co - Lbl-024 Receives Ind Approval from Nmpa for Metastatic Colorectal Cancer

THOMSON REUTERS

Nanjing Leads Biolabs Says China Regulator Clears IND for Lbl-024 in Metastatic Colorectal Cancer

Movement Alert｜LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment

LEADS BIOLABS-B (09887) Records 346 Million Hong Kong Dollar Share Transfer, Representing 3.39% of Total Shares

Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Completes Patient Enrollment in Phase Ii Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors

THOMSON REUTERS

Leads Biolabs completes full enrollment of 70-patient Phase II trial for bispecific antibody LBL-024 in first-line advanced biliary tract cancer

Bulletin Express

Nanjing Leads Biolabs Completes Enrollment in Phase II Opamtistomig Trial for Advanced Biliary Tract Cancer

LEADS BIOLABS-B (09887) Records a Major Securities Transfer Valued at HK$746 Million, Representing 7.10% of Total Shares, with 13.76 Million Shares Moved from China Securities Depository and Clearing Hong Kong

Hong Kong Stocks Update: LEADS BIOLABS-B (09887) Drops Over 7% Further, Kpc Pharmaceuticals Plans to Sell HKD 132 Million Stake, Founder Voluntarily Extends Lock-Up Period

Movement Alert｜LEADS BIOLABS-B Falls 5.51% in Regular Trading, Lock-Up Expiry Triggers Selling Pressure as Kunming Pharma Exits Position

KPC Pharmaceuticals to Divest Stake in Nanjing Leads Biolabs

MT Newswires Live

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://sg.etasphere.com/stock/09887/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":57,"timestamp":1789973019600,"preClose":55.75,"halted":0,"volume":1731700,"delay":0,"changeRate":0.02242152466367713,"floatShares":198000000,"shares":199000000,"eps":-1.4179984152388128,"marketStatus":"Trading","change":1.25,"latestTime":"09-21 14:43:45","open":57.05,"high":59.15,"low":55.4,"amount":99348060,"amplitude":0.067265,"askPrice":57,"askSize":2500,"bidPrice":56.85,"bidSize":2000,"shortable":3,"etf":0,"ttmEps":-1.6137665733069733,"tradingStatus":2,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1789978200000},"marketStatusCode":2,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":55.75,"openAndCloseTimeList":[[1789954200000,1789963200000],[1789966800000,1789977600000]],"volumeRatio":0.760875,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":198000000,"roa":"-12.87%","roe":"-51.55%","lyrEps":-1.417998,"volumeRatio":0.760875,"shares":199000000,"dividePrice":0,"high":59.15,"amplitude":0.067265,"preClose":55.75,"low":55.4,"week52Low":44.72,"pbRate":"10.40","psRate":"45.39","week52High":97.5,"institutionHeld":0,"latestPrice":57,"committee":-0.111111,"eps":-1.4179984152388128,"divideRate":0,"volume":1731700,"delay":0,"ttmEps":-1.6137665733069733,"open":57.05,"prevYearClose":51,"prevWeekClose":55.75,"prevMonthClose":72.3,"prevQuarterClose":49.32,"fiveDayClose":61.5,"twentyDayClose":69.05,"sixtyDayClose":49.58},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2026-08-31","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1788139800000,"name":null,"time":"","dateTimestamp":1788105600000,"actualEps":null},{"date":"2026-03-27","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774575000000,"name":null,"time":"","dateTimestamp":1774540800000,"actualEps":null},{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":3,"updateTime":1789574400000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-09-18","current":-35.011688,"percent":0.795053,"low":-76.458084,"twenty":-45.532372,"median":-39.845109,"eighty":-34.761336,"high":-30.202688,"avg":-41.959033,"sd":9.633296,"marketCap":10878029200},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000},{"date":"2026-02-27","current":-37.9711,"twenty":-42.061223,"median":-38.358648,"eighty":-33.438876,"marketCap":12470515860},{"date":"2026-03-06","current":-32.876582,"twenty":-42.035836,"median":-37.973315,"eighty":-33.326804,"marketCap":10710323430},{"date":"2026-03-13","current":-37.800338,"twenty":-41.938243,"median":-37.9711,"eighty":-33.411645,"marketCap":12371069960},{"date":"2026-03-20","current":-39.652105,"twenty":-41.914066,"median":-38.162788,"eighty":-33.431073,"marketCap":12927967000},{"date":"2026-03-27","current":-45.563334,"twenty":-41.938243,"median":-38.422097,"eighty":-33.438876,"marketCap":14817439100},{"date":"2026-04-02","current":-73.055706,"twenty":-42.061577,"median":-38.676054,"eighty":-33.441386,"marketCap":17572695150},{"date":"2026-04-10","current":-74.98239,"twenty":-42.364587,"median":-38.815397,"eighty":-33.443763,"marketCap":18175244000},{"date":"2026-04-17","current":-69.940613,"twenty":-42.73421,"median":-39.081216,"eighty":-33.482556,"marketCap":16960268450},{"date":"2026-04-24","current":-67.940785,"twenty":-43.090538,"median":-39.261059,"eighty":-33.558052,"marketCap":16476253800},{"date":"2026-04-30","current":-65.13036,"twenty":-44.026925,"median":-39.582143,"eighty":-33.605745,"marketCap":15804560000},{"date":"2026-05-08","current":-55.847576,"twenty":-44.547984,"median":-39.760016,"eighty":-33.640661,"marketCap":16030679080},{"date":"2026-05-15","current":-43.849045,"twenty":-45.37348,"median":-39.795589,"eighty":-33.697999,"marketCap":12619684710},{"date":"2026-05-22","current":-44.434352,"twenty":-44.931837,"median":-39.87359,"eighty":-33.778461,"marketCap":12758908970},{"date":"2026-05-29","current":-42.313126,"twenty":-44.693978,"median":-39.965338,"eighty":-33.850015,"marketCap":12192067340},{"date":"2026-06-05","current":-38.943344,"twenty":-44.633844,"median":-39.952945,"eighty":-33.989804,"marketCap":11237386700},{"date":"2026-06-12","current":-37.176407,"twenty":-44.416359,"median":-39.831455,"eighty":-34.116239,"marketCap":10720268020},{"date":"2026-06-18","current":-37.166904,"twenty":-44.344385,"median":-39.795685,"eighty":-34.459057,"marketCap":10740157200},{"date":"2026-06-26","current":-34.282345,"twenty":-44.322103,"median":-39.774315,"eighty":-34.282345,"marketCap":9861055444},{"date":"2026-07-03","current":-36.446991,"twenty":-44.194662,"median":-39.640092,"eighty":-34.070689,"marketCap":10491542450},{"date":"2026-07-10","current":-34.534018,"twenty":-44.124681,"median":-39.536207,"eighty":-34.070689,"marketCap":9928678656},{"date":"2026-07-17","current":-44.462046,"twenty":-44.326559,"median":-39.640092,"eighty":-34.242022,"marketCap":12828521100},{"date":"2026-07-24","current":-43.03924,"twenty":-44.356568,"median":-39.788614,"eighty":-34.393423,"marketCap":12420792910},{"date":"2026-07-31","current":-36.732388,"twenty":-44.331016,"median":-39.652105,"eighty":-34.443911,"marketCap":10620822120},{"date":"2026-08-07","current":-44.144483,"twenty":-44.255348,"median":-39.774315,"eighty":-34.478204,"marketCap":12788742740},{"date":"2026-08-14","current":-50.259709,"twenty":-44.44543,"median":-39.795685,"eighty":-34.516798,"marketCap":14578768940},{"date":"2026-08-21","current":-48.712147,"twenty":-45.096211,"median":-39.845109,"eighty":-34.555887,"marketCap":14161096160},{"date":"2026-08-28","current":-49.214108,"twenty":-45.572671,"median":-39.940552,"eighty":-34.653517,"marketCap":14310265010},{"date":"2026-09-04","current":-40.091985,"twenty":-45.572671,"median":-40.024301,"eighty":-34.737896,"marketCap":12487782400},{"date":"2026-09-11","current":-37.6607,"twenty":-45.564242,"median":-39.940552,"eighty":-34.761336,"marketCap":11746320320},{"date":"2026-09-18","current":-34.8313,"twenty":-45.532372,"median":-39.845109,"eighty":-34.761336,"marketCap":10878029200}],"updateTime":1789961379773},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657572869","title":"Nanjing Leads Biolabs Says Phase II Opamtistomig Trial in First-Line Liver Cancer Enters Expansion Phase","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572869","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572869?lang=en_us&edition=fundamental","pubTime":"2026-08-06 07:00","pubTimestamp":1785970810,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says Phase II Opamtistomig trial in first-line liver cancer enters expansion phaseNanjing Leads Biolabs reported its Phase II study of LBL-024 (opamtistomig) for first-line hepat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260805:nNDL4Rzf09:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000252152.HKD","09887","BK1161","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1131250364","title":"Leads Biolabs: Phase II Opamtistomig Trial for First-Line Liver Cancer Enters Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1131250364","media":"Bulletin Express","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1131250364?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:25","pubTimestamp":1785968734,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) reported that its self-developed PD-L1/4-1BB bispecific antibody, Opamtistomig (LBL-024), has completed the safety run-in of a Phase II study in...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1193898777","title":"LEADS BIOLABS-B Advances Phase II Study of Vilitis™ in Hepatocellular Carcinoma to Expansion Stage","url":"https://stock-news.laohu8.com/highlight/detail?id=1193898777","media":"Stock News","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1193898777?lang=en_us&edition=fundamental","pubTime":"2026-08-06 06:20","pubTimestamp":1785968415,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) has announced that its independently developed PD-L1/4-1BB bispecific antibody, Opatsosumimab (Vilitis™), has successfully completed the safety run-in assessment in a Phase II...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD","BK1161","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656055321","title":"Leads Biolabs Announces Partner Oblenio Bio Doses First Patients in Phase 1a Trial of Lbl‑051 for Refractory Autoimmune Diseases","url":"https://stock-news.laohu8.com/highlight/detail?id=2656055321","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656055321?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:56","pubTimestamp":1785844585,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nTUA5J5NW3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252160.HKD","HK0000500386.USD","BK1161","HK0000252152.HKD","09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152365137","title":"Leads Biolabs’ partner Oblenio opens Phase Ia trial for trispecific T-cell engager LBL-051; company clarifies connected share-award transaction","url":"https://stock-news.laohu8.com/highlight/detail?id=1152365137","media":"Bulletin Express","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152365137?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:24","pubTimestamp":1785842650,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) announced that Oblenio Bio, its NewCo partner formed with Aditum Bio, has administered first doses to patients in a European Phase Ia, first-in-human...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656853074","title":"Nanjing Leads Biolabs Clarifies Award Grant to Executive Director is Exempt Connected Transaction Under HK Rules","url":"https://stock-news.laohu8.com/highlight/detail?id=2656853074","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656853074?lang=en_us&edition=fundamental","pubTime":"2026-08-04 19:10","pubTimestamp":1785841828,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs clarifies award grant to executive director is exempt connected transaction under HK rulesNanjing Leads Biolabs issued a supplemental clarification on its July 1, 2026 award gran","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260804:nNDL1LdRlk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","BK1161","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656342024","title":"Leads Biolabs' Pd-L1/4-1Bb Bispecific Antibody Ind Application for Combination Therapy in Metastatic Colorectal Cancer Approved, Further Strengthening Gastrointestinal Oncology Franchise","url":"https://stock-news.laohu8.com/highlight/detail?id=2656342024","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656342024?lang=en_us&edition=fundamental","pubTime":"2026-08-03 11:43","pubTimestamp":1785728605,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260803:nTUA6LLSYN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","HK0000252152.HKD","HK0000500386.USD","BK1161","HK0000252160.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1122893332","title":"LEADS BIOLABS-B shares climb nearly 6% as PD-L1/4-1BB bispecific antibody gets IND clearance for advanced colorectal cancer treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=1122893332","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1122893332?lang=en_us&edition=fundamental","pubTime":"2026-08-03 10:32","pubTimestamp":1785724340,"startTime":"0","endTime":"0","summary":"Shares of LEADS BIOLABS-B (09887) rose nearly 6% in early trading, last up 5.71% at HK$56.45 with a turnover of HK$75.0476 million.On August 3, the company announced that China's National Medical...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["KCAI","HK0000500386.USD","BK4585","HK0000252152.HKD","09887","VXUS","HK0000252160.HKD","IND","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168072852","title":"LEADS BIOLABS-B Shares Shift with HK$364 Million in Custody Transfers, Representing 3.62% of Total","url":"https://stock-news.laohu8.com/highlight/detail?id=1168072852","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168072852?lang=en_us&edition=fundamental","pubTime":"2026-08-03 08:50","pubTimestamp":1785718227,"startTime":"0","endTime":"0","summary":"Data from the Hong Kong Stock Exchange shows that on July 31, LEADS BIOLABS-B (09887) experienced a notable change in share custody, with a total transfer value of HK$364 million, accounting for...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","BK1161","HK0000252160.HKD","HK0000500386.USD","161027"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656456073","title":"Nanjing Leads Biolabs Co - Lbl-024 Receives Ind Approval from Nmpa for Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656456073","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656456073?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:05","pubTimestamp":1785708356,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260802:nFWN43Z00C:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000252160.HKD","HK0000252152.HKD","BK1161","09887","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656345985","title":"Nanjing Leads Biolabs Says China Regulator Clears IND for Lbl-024 in Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2656345985","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656345985?lang=en_us&edition=fundamental","pubTime":"2026-08-03 06:05","pubTimestamp":1785708354,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs says China regulator clears IND for LBL-024 in metastatic colorectal cancerNanjing Leads Biolabs secured China NMPA clearance to start a new clinical trial of PD-L1/4-1BB bispeci","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260802:nNDL1zTHz6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","09887","HK0000500386.USD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1181232541","title":"Movement Alert｜LEADS BIOLABS-B Rises 5.11% in Regular Trading, Core Pipeline Cholangiocarcinoma Phase II Study Completes Full Patient Enrollment","url":"https://stock-news.laohu8.com/highlight/detail?id=1181232541","media":"Market Focus","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181232541?lang=en_us&edition=fundamental","pubTime":"2026-07-31 10:03","pubTimestamp":1785463394,"startTime":"0","endTime":"0","summary":"On July 31, LEADS BIOLABS-B rose 5.11% in regular trading, trading at HK$52.9/share, with turnover of HK$37.318 million.On the news front, the company announced on July 30 that its core drug...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Leads Biolabs-B Rises; Core Cholangiocarcinoma Phase II Trial Fully Enrolled","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1133179762","title":"LEADS BIOLABS-B (09887) Records 346 Million Hong Kong Dollar Share Transfer, Representing 3.39% of Total Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1133179762","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133179762?lang=en_us&edition=fundamental","pubTime":"2026-07-31 08:30","pubTimestamp":1785457819,"startTime":"0","endTime":"0","summary":" LEADS BIOLABS-B (09887) reported a significant change in its share position on July 30, with a total transfer value of 346 million Hong Kong dollars, accounting for 3.39% of its total shares.The...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000252160.HKD","09887","BK1161","161027","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655737958","title":"Leads Biolabs’ Opamtistomig (Pd-L1/4-1Bb Bispecific Antibody) Completes Patient Enrollment in Phase Ii Study for Biliary Tract Cancer, Further Demonstrating Breakthrough Potential in Immune-Cold Tumors","url":"https://stock-news.laohu8.com/highlight/detail?id=2655737958","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655737958?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:36","pubTimestamp":1785407788,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nTUA5JD7ZJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["09887","HK0000500386.USD","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1157244498","title":"Leads Biolabs completes full enrollment of 70-patient Phase II trial for bispecific antibody LBL-024 in first-line advanced biliary tract cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1157244498","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1157244498?lang=en_us&edition=fundamental","pubTime":"2026-07-30 18:28","pubTimestamp":1785407280,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Leads Biolabs) has finalized patient recruitment for its Phase II clinical study of Opamtistomig (LBL-024), a PD-L1/4-1BB bispecific antibody, in first-line treatment...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655827075","title":"Nanjing Leads Biolabs Completes Enrollment in Phase II Opamtistomig Trial for Advanced Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2655827075","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655827075?lang=en_us&edition=fundamental","pubTime":"2026-07-30 17:46","pubTimestamp":1785404807,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs completes enrollment in Phase II Opamtistomig trial for advanced biliary tract cancerNanjing Leads Biolabs completed full enrollment of 70 patients in a Phase II study of LBL-024","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL2w0tzp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","09887","BK1161","HK0000252160.HKD","HK0000500386.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103606796","title":"LEADS BIOLABS-B (09887) Records a Major Securities Transfer Valued at HK$746 Million, Representing 7.10% of Total Shares, with 13.76 Million Shares Moved from China Securities Depository and Clearing Hong Kong","url":"https://stock-news.laohu8.com/highlight/detail?id=1103606796","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103606796?lang=en_us&edition=fundamental","pubTime":"2026-07-30 08:28","pubTimestamp":1785371298,"startTime":"0","endTime":"0","summary":"A significant change in the shareholding position of LEADS BIOLABS-B (09887) was recorded on July 29, according to the latest data from the Hong Kong Stock Exchange. The total market value of the...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["161027","BK1161","09887","HK0000500386.USD","HK0000252160.HKD","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161348079","title":"Hong Kong Stocks Update: LEADS BIOLABS-B (09887) Drops Over 7% Further, Kpc Pharmaceuticals Plans to Sell HKD 132 Million Stake, Founder Voluntarily Extends Lock-Up Period","url":"https://stock-news.laohu8.com/highlight/detail?id=1161348079","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161348079?lang=en_us&edition=fundamental","pubTime":"2026-07-28 14:18","pubTimestamp":1785219500,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) shares tumbled more than 7% in early trading, adding to recent losses. As of the latest check, the stock was down 6.89% to HKD 54.05, with turnover reaching HKD 608 million....","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","HK0000252160.HKD","HK0000500386.USD","KCAI","BK4585","VXUS","09887","BK0188","BK1161","600422","BK4588","BK0060","BK0239","HK0000252152.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1119611130","title":"Movement Alert｜LEADS BIOLABS-B Falls 5.51% in Regular Trading, Lock-Up Expiry Triggers Selling Pressure as Kunming Pharma Exits Position","url":"https://stock-news.laohu8.com/highlight/detail?id=1119611130","media":"Market Focus","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1119611130?lang=en_us&edition=fundamental","pubTime":"2026-07-28 09:43","pubTimestamp":1785202996,"startTime":"0","endTime":"0","summary":"On July 28, LEADS BIOLABS-B fell 5.51% in regular trading, trading at HK$56.7/share with turnover of HK$360 million, extending the prior session's decline.On the news front, the stock is facing...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"LEADS BIOLABS-B Falls as Lock-Up Expiry Triggers Selling Pressure as Kunming Pharma Exits Position","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654139620","title":"KPC Pharmaceuticals to Divest Stake in Nanjing Leads Biolabs","url":"https://stock-news.laohu8.com/highlight/detail?id=2654139620","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654139620?lang=en_us&edition=fundamental","pubTime":"2026-07-27 16:46","pubTimestamp":1785142001,"startTime":"0","endTime":"0","summary":"KPC Pharmaceuticals  will sell 2.4 million shares it holds in Nanjing Leads Biolabs  for a total of 132.2 million yuan, according to a Saturday disclosure to the Shanghai bourse.The divestment of the 1.2283% stake will help KPC focus on its core business and optimize its asset structure.The selling price will be determined according to the secondary market price of the time.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK0060","HK0000252160.HKD","600422","HK0000500386.USD","BK0028","BK0239","BK1161","HK0000252152.HKD","BK0188","09887"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":8,"pageCount":3,"totalSize":141,"code":"91000000","status":"200"}]}}